BNET Industries
Sciele Pharma Inc. (SCRX) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $382.2M
- Profit
- Dec 31 2007
- $45.4M
- Market Cap
- Oct 03 2008
- $974.5M
Latest News and Analysis
Shionogi and Sciele Announce Receipt of United States Antitrust Clearance
OSAKA, Japan & ATLANTA -- Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced today that the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976 with respect to Shionogi's indirect wholly owned subsidiary's cash tender offer for all outstanding shares of common...
LifeCycle Pharma Sells Fenoglide™ Royalty Stream to Cowen Healthcare Royalty Partners for up to USD 105 Million Including an Upfront Payment of USD 29 Million
LifeCycle Pharma Adjusts Expectations for 2008 HORSHOLM, Denmark -- LifeCycle Pharma A/S (OMX: LCP) announced today that the royalty stream in North America related to its first commercialized product, Fenoglide[TM], the cholesterol lowering drug (formerly known as LCP-FenoChol) for the treatment of hyperlipidemia and hypertriglyceridemia, has been sold...
Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
DURHAM, N.C., Aug. 19 /PRNewswire/ -- Addrenex Pharmaceuticals ( http://www.addrenex.com/ ) has made three strategic hires this month to further its goal of identifying and developing as many new drug candidates as possible over the next 18 months. The fast-paced timeline they have set for drug discovery...
Sciele Pharma, Inc. Reports Results for the Second Quarter of 2008
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX): Second quarter 2008 financial results include: * Pro forma net revenues, a non-GAAP measure, were $111.3 million, excluding $8.1 million in charges related to Sular returns (see note a to the financial statements accompanying this release), an increase of 17%...
BellwetherReport.com Analyst Report on SINA, BIDU, SCRX and KLAC
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Mylan Launches First Generic Version of Antihypertensive Sular® ER in the United States
PITTSBURGH, July 28 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Nisoldipine Extended-release ER Tablets, 20 mg, 30 mg and 40 mg. ...
Sciele Pharma Completes Phase III Safety Trial for Glycopyrrolate Liquid, a Treatment for Chronic, Moderate-to-Severe Drooling in Pediatric Patients
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has completed its phase III safety trial utilizing a liquid formulation of glycopyrrolate to treat chronic, moderate-to-severe drooling in pediatric patients. This condition often results from cerebral palsy as well as from other neurological disorders. This trial...
Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals, Inc. to develop and market ADX415, a novel patented, centrally-acting alpha adrenergic receptor agonist, specific to Alpha-2 receptors, for the treatment of hypertension and other potential indications. Under the...
FDA Approves PrandiMet™, a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes
ATLANTA & PRINCETON, N.J. -- Sciele Pharma, Inc. (NASDAQ:SCRX) and Novo Nordisk Inc. today announced that the U.S. Food and Drug Administration FDA approved PrandiMet[TM] repaglinide and metformin HCl tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin([R])) and insulin...
SupplyScape Selected by Sciele Pharma for Transaction and Product Security
SupplyScape helps pharmaceutical company improve product security, expand supply chain visibility and maintain focus on patient safety WOBURN, Mass. -- SupplyScape Corporation, the leading provider of software to secure the safety and value of the pharmaceutical supply chain, today announced that Sciele[R] Pharma, Inc. has...
Zacks Bull and Bear of the Day Highlights: Sciele Pharmaceuticals, Avnet, Berkshire Hathaway, Eli Lilly and Anglo American
CHICAGO -- Zacks Equity Research highlights Sciele Pharmaceuticals (Nasdaq: SCRX) as the Bull of the Day and Avnet, Inc. (NYSE: AVT) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Berkshire Hathaway (NYSE: BRK.A), Eli Lilly & Co. (NYSE: LLY) and Anglo...
Sciele Pharma to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that Ed Schutter, President and Chief Operating Officer, will make a presentation at the Goldman Sachs 29th Annual Global Healthcare Conference at the Ritz-Carlton Laguna Niguel in Dana Point, California on Wednesday, June 11, at...
Sciele Pharma Announces That Addrenex Has Completed Enrollment of Pivotal Phase III Trial for Clonicel for ADHD
ATLANTA -- Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, today announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder ADHD in children. Addrenex is also continuing to enroll patients in...
Sciele Pharma to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that Ed Schutter, President and Chief Operating Officer, will make a presentation at the UBS Global Specialty and Generic Pharmaceuticals Conference at the Waldorf Hilton Hotel in London on Thursday, May 29, 2008, at 11:00 a.m. local time...
Sciele Pharma to Present at Bank of America Health Care Conference
ATLANTA -- Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, today announced that Ed Schutter, President and Chief Operating Officer, will make a presentation at the Bank of America Health Care Conference at the Four Seasons in Las Vegas, on Tuesday, May 13, 2008, at 12:40 p.m. Pacific Time...
Sciele Pharma, Inc. Reports Results for the First Quarter of 2008
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX): First quarter 2008 financial results include: * Revenues were $100.4 million, an increase of 22% over the first quarter of 2007. * Diluted earnings per share were $0.32 (inclusive of a non-cash impairment charge totaling $0.03 per share)...
Sciele Pharma, Inc. Adopts $100 Million Share Repurchase Program
Approves Redemption of Poison Pill ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that its Board of Directors has adopted a new share repurchase program, authorizing the repurchase of up to $100 million of its outstanding shares of common stock over the next 12...
Sciele Pharma Announces FDA Acceptance of NDA for Addrenex Pharmaceuticals' CloniBID to Treat Hypertension
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration FDA has accepted the New Drug Application NDA submitted by Addrenex Pharmaceuticals for CloniBID to treat hypertension. The FDA has assigned a Prescription Drug User Fee Act PDUFA date of December 19, 2008. Upon FDA...
Sciele Pharma Announces First Quarter 2008 Earnings Release Date and Conference Call
ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, will release financial results for the first quarter ended March 31, 2008, after the market closes on Wednesday, April 30, 2008. Conference Call Sciele will also host a conference call on Wednesday, April 30, beginning at...
(SCRX) SqueezeTrigger Price is $20.233. There is $201,767,118.00 That Short Sellers Still Need To Cover.
M2 PRESSWIRE-1 April 2008-BUYINS.NET: SCRX SqueezeTrigger Price is $20.233. There is $201,767,118.00 That Short Sellers Still Need To CoverC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET / www.squeezetrigger.com is monitoring Sciele Pharma, Inc. - Common Stock (NASDAQ:SCRX) in real time and...
- Next »
- page 1 of 1
- « Previous
- Incorporated: 1992
- CEO: Mr. Patrick P. Fourteau
- Employees: 920
Sciele Pharma is engaged in marketing and development of prescription products focused on Cardiovascular, Diabetes, Women's Health, and Pediatric treatment. Co.'s Cardiovascular, Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina, and Type 2 Diabetes. Co.'s Women's Health products are designed to improve the health and well-being of women of all ages, as well as expectant and nursing mothers and their babies. Co.'s Pediatric product focus includes the sub-specialties of allergy and immunology, psychiatry, neurology, urology and infectious diseases. As of Dec 31 2007, Co. marketed and sold 21 products, 11 of which are actively promoted.
Key Competitors
Sciele Pharma Inc. Company Info
Board of Directors
Mr. Pierre Lapalme
Chairman
Mr. Patrick P. Fourteau
Mr. Jerry N. Ellis
Dr. Jerry C. Griffin M.D.
Mr. William J. Robinson
Mr. Jon S. Saxe
Mr. Patrick J. Zenner
Contact Information
6195 Shiloh Road
Alpharetta, GA
770 442-9707
NAICS Code
Drugs and Druggists' Sundries Merchant Wholesalers: 424210
